Fecal Calprotectin in Cystic Fibrosis
NCT00863694 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106
Last updated 2013-12-13
Summary
Elevated fecal calprotectin is a biomarker for intestinal inflammation in cystic fibrosis
Conditions
Sponsors & Collaborators
-
Medical College of Wisconsin
lead OTHER
Principal Investigators
-
Steven Werlin, MD · Medical College of Wisconsin
Eligibility
- Min Age
- 1 Month
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-02-28
- Primary Completion
- 2013-08-31
- Completion
- 2013-08-31
Countries
- United States
Study Locations
More Related Trials
-
COVID-19 Antibody Responses In Cystic Fibrosis
NCT04863573 ·Status: UNKNOWN
-
Ocular Surface Changes in Patients With Cystic Fibrosis
NCT00345280 ·Status: UNKNOWN
-
Exocrine Pancreatic Function Testing in Cystic Fibrosis
NCT01446861 ·Status: UNKNOWN
-
Gene Modifiers of Cystic Fibrosis Lung Disease
NCT00037765 ·Status: ACTIVE_NOT_RECRUITING
-
Diagnosis and Treatment of Patients With Cystic Fibrosis
NCT00001223 ·Status: TERMINATED
-
Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis
NCT04016571 ·Status: COMPLETED
-
Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects
NCT01078740 ·Status: COMPLETED
-
Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations
NCT00381628 ·Status: COMPLETED
-
The Role of Bacteria and Genetic Variations in Cystic Fibrosis
NCT00043225 ·Status: COMPLETED
-
Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies
NCT00727285 ·Status: COMPLETED
-
A Novel Assay to Quantify Treatment Response in Cystic Fibrosis (CF)
NCT01626157 ·Status: COMPLETED
-
Structure and Function of Salivary Proteins
NCT00916682 ·Status: UNKNOWN
-
Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung
NCT01805713 ·Status: COMPLETED
-
COVID-19 Antibody Responses In Cystic Fibrosis
NCT04904445 ·Status: COMPLETED
-
Host and Bacterial Mechanisms During Cystic Fibrosis Pulmonary Exacerbations
NCT04354038 ·Status: COMPLETED
-
COVID-19 Antibody Responses in Cystic Fibrosis
NCT05614336 ·Status: COMPLETED ·Phase: NA
-
Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis
NCT02308267 ·Status: UNKNOWN
-
Zinc Homeostasis and Kinetics in Children With Cystic Fibrosis (CF)
NCT00104494 ·Status: COMPLETED ·Phase: NA
-
Quantification of Pulmonary Neutrophil Activity in Cystic Fibrosis Using Radiolabeled Fluorodeoxyglucose and PET Imaging
NCT00023465 ·Status: UNKNOWN
-
Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
NCT06506773 ·Status: COMPLETED
-
Small Intestinal Function in Patients With Cystic Fibrosis
NCT01468428 ·Status: UNKNOWN
-
Platelets in Cystic Fibrosis Lung Inflammation
NCT05339724 ·Status: COMPLETED
-
Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis
NCT00750932 ·Status: COMPLETED
-
Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients
NCT00004296 ·Status: COMPLETED
-
Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function
NCT01494909 ·Status: COMPLETED ·Phase: NA